At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,490 enrolled
Drug / intervention
Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin-17 levelsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Validation of Blood Test Finding for the Diagnosis of Gastritis and Gastric Neoplasms
In Brief
An observational study evaluating Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin-17 levels for Cancer Screening Tests. Completed, enrolled 1,490 participants across 1 site.
Detailed Summary
Helicobacter pylori infection rate is decreasing in younger population; however, biennial gastroscopy is still recommended for all Koreans aged between 40 and 75 years. This study aimed to validate blood tests for gastric cancer screening according to the infection status of H. pylori (naive, current, and past infection).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer Screening Tests
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartMay 2023
First PostedMay 2023
Primary CompletionAug 2024
TodayJul 2026
First PostedMay 31, 2023
Enrollment StartMay 1, 2023
Primary CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.1 years ago
Interventions
Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin-17 levelsother
Endoscopic biopsy